MDxHealth and AceCGT Group - Collaborative Distribution Agreement
Back Download
MDxHealth and AceCGT Group - Collaborative Distribution Agreement - SelectMDx for Prostate Cancer - December 19, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today that it has signed a collaborative distribution agreement with AceCGT Group for their SelectMDx(TM) for Prostate Cancer assay in Hong Kong and Macao, Special Administrative Regions of the People's Republic of China. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer.  SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection.  At AceCGT Diagnostic, we strongly believed that screening and diagnostic tests are the foundation of a successful health care system by providing critical information for both health care providers and patients to make the right medical decisions.  Hence, SelectMDx for Prostate Cancer is an excellent match for our company. Quoted:'In 2013, prostate cancer was the third most common cancer in men and accounted for 11.1% of all new cancer cases in males.  Prostate cancer recorded the largest increase in incidence rate among the common male cancers in Hong Kong during the past two decades.' For detail please visit: About MDxHealth - MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.  The Company's European headquarters are in Belgium, its US headquarters and laboratory operations based in Irvine, California.
#SelectMDx for Prostate Cancer #liquid biopsy#MDxHealth #Prostate Cancer #proprietary urine-based
Related Coverage